Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 5/12/22 → 2/6/26 |
Funding
- AstraZeneca Pharmaceuticals LP (domestic): $24,281.00
22-LUN-127-AZ: A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Fo
- Villano, PhD, John (PI)
- Zinner, Ralph (Former PI)